{"transactions":[{"id":760236,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-05-28T23:24:33.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."}],"balance_after":16000,"derivative":{"exercise_price":9.1,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-038963","document":"wk-form4_1780010671.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038963/wk-form4_1780010671.xml","form_type":"4"}},{"id":760235,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T23:24:33.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":39806,"source":{"system":"sec-edgar","filing":"0001628280-26-038963","document":"wk-form4_1780010671.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038963/wk-form4_1780010671.xml","form_type":"4"}},{"id":1127701,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2025-06-02T23:20:51.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares subject to the stock option will vest and become exercisable in full on May 30, 2026."}],"balance_after":16000,"derivative":{"exercise_price":4.94,"exercise_date":"2026-05-30","expiration_date":"2035-05-29","underlying":"Common  Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-25-028892","document":"wk-form4_1748906445.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028892/wk-form4_1748906445.xml","form_type":"4"}},{"id":1127700,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T23:20:51.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on  May 30, 2026."}],"balance_after":31806,"source":{"system":"sec-edgar","filing":"0001628280-25-028892","document":"wk-form4_1748906445.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028892/wk-form4_1748906445.xml","form_type":"4"}},{"id":1495191,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-03T15:59:32.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":10.39,"exercise_date":"2025-05-30","expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-24-026193","document":"wk-form4_1717430363.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024026193/wk-form4_1717430363.xml","form_type":"4"}},{"id":1495190,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-03T15:59:32.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":23806,"source":{"system":"sec-edgar","filing":"0001628280-24-026193","document":"wk-form4_1717430363.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024026193/wk-form4_1717430363.xml","form_type":"4"}},{"id":1879788,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-24T18:34:41.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":12054,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12054,"derivative":{"exercise_price":25.74,"exercise_date":"2024-05-22","expiration_date":"2033-05-21","underlying":"Common Stock","underlying_shares":12054},"source":{"system":"sec-edgar","filing":"0001209191-23-031841","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123031841/doc4.xml","form_type":"4"}},{"id":1879787,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T18:34:41.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":6027,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15806,"source":{"system":"sec-edgar","filing":"0001209191-23-031841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123031841/doc4.xml","form_type":"4"}},{"id":2256808,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-25T21:51:45.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":12810,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12810,"derivative":{"exercise_price":24.14,"exercise_date":"2023-05-23","expiration_date":"2032-05-22","underlying":"Common Stock","underlying_shares":12810},"source":{"system":"sec-edgar","filing":"0001209191-22-031949","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122031949/doc4.xml","form_type":"4"}},{"id":2256807,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T21:51:45.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":6405,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9779,"source":{"system":"sec-edgar","filing":"0001209191-22-031949","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122031949/doc4.xml","form_type":"4"}},{"id":2697031,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-25T20:35:38.000Z","date":"2021-05-21","kind":"grant","acquired":true,"shares":6748,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6748,"derivative":{"exercise_price":45.28,"exercise_date":"2022-05-21","expiration_date":"2031-05-20","underlying":"Common Stock","underlying_shares":6748},"source":{"system":"sec-edgar","filing":"0001209191-21-035706","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121035706/doc4.xml","form_type":"4"}},{"id":2697030,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-25T20:35:38.000Z","date":"2021-05-21","kind":"grant","acquired":true,"shares":3374,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3374,"source":{"system":"sec-edgar","filing":"0001209191-21-035706","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121035706/doc4.xml","form_type":"4"}},{"id":2874035,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-02-08T22:40:28.000Z","date":"2021-02-04","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vest monthly over a three year period, subject to Reporting Person's continued service on the Board."}],"balance_after":25000,"derivative":{"exercise_price":20.5,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-21-005208","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000089924321005208/doc4.xml","form_type":"4"}},{"id":2948736,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-11T21:42:49.000Z","date":"2020-12-09","kind":"grant","acquired":true,"shares":46500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares subject to the stock option vest and become exercisable on December 9, 2021, and the remaining shares vest in 24 equal monthly installments thereafter."}],"balance_after":46500,"derivative":{"exercise_price":29.43,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":46500},"source":{"system":"sec-edgar","filing":"0001209191-20-062955","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919120062955/doc4.xml","form_type":"4"}},{"id":3136537,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-22T21:35:22.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the \"Plan\") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date."}],"balance_after":24000,"derivative":{"exercise_price":0.6261,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-20-031843","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000120919120031843/doc4.xml","form_type":"4"}},{"id":3156059,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-08T21:02:40.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":1428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 6, 2021 or (ii) the Issuer's 2021 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":1428,"derivative":{"exercise_price":3.65,"expiration_date":"2030-05-06","underlying":"Common Stock","underlying_shares":1428},"source":{"system":"sec-edgar","filing":"0001209191-20-027974","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339970/000120919120027974/doc4.xml","form_type":"4"}},{"id":3480929,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-21T21:14:00.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the \"Plan\") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date."}],"balance_after":12000,"derivative":{"exercise_price":2.36,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-038561","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000120919119038561/doc4.xml","form_type":"4"}},{"id":3531215,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-10T21:22:24.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 8, 2020 or (ii) the Issuer's 2020 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":20000,"derivative":{"exercise_price":0.5834,"expiration_date":"2029-05-08","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-029039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339970/000120919119029039/doc4.xml","form_type":"4"}},{"id":3687824,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-25T01:25:26.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option vests on January 22, 2020, and the remainder vests in equal monthly installments thereafter over 36 months."}],"balance_after":525000,"derivative":{"exercise_price":4.63,"expiration_date":"2029-01-22","underlying":"Common Stock","underlying_shares":525000},"source":{"system":"sec-edgar","filing":"0000899243-19-001927","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000089924319001927/doc4.xml","form_type":"4"}},{"id":3881171,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-28T20:38:13.000Z","date":"2018-06-27","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the \"Plan\") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date."}],"balance_after":12000,"derivative":{"exercise_price":6.46,"expiration_date":"2028-06-26","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-039879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000120919118039879/doc4.xml","form_type":"4"}},{"id":3927575,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-17T20:27:52.000Z","date":"2018-05-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 15, 2019 or (ii) the Issuer's 2019 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors."}],"balance_after":20000,"derivative":{"exercise_price":1.35,"expiration_date":"2028-05-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-18-030915","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339970/000120919118030915/doc4.xml","form_type":"4"}},{"id":4036547,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-23T22:00:42.000Z","date":"2018-02-22","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option vests on February 22, 2019, and the remainder vests in equal monthly installments thereafter over 36 months."}],"balance_after":275000,"derivative":{"exercise_price":7.77,"expiration_date":"2028-02-22","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0000899243-18-005333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000089924318005333/doc4.xml","form_type":"4"}},{"id":4092273,"issuer":{"id":94539,"kind":"organization","name":"INVIVO THERAPEUTICS HOLDINGS CORP.","symbol":"NVIV"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-23T21:22:11.000Z","date":"2018-01-19","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal installments on each monthly anniversary of the date of grant until fully vested on the first anniversary of the date of grant, provided that such director remains a director of our company on each such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":0.69,"expiration_date":"2028-01-19","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001179110-18-001044","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1292519/000117911018001044/edgar.xml","form_type":"4"}},{"id":4118850,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-29T21:30:39.000Z","date":"2017-12-29","kind":"grant","acquired":true,"shares":1100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This option was granted on October 9, 2017, subject to vesting based on the Issuer's stock price appreciation and certain financial performance goals. The financial performance goals were waived on December 29, 2017 and therefore the option is deemed a reportable derivative security as of such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable based on the Issuer's common stock price during the two years after the first anniversary of the date of grant as follows: 25% of shares subject to the option vest after the stock price is equal to or greater than $10.00 per share for 20 consecutive trading days; and an additional 6.25% of the shares subject to the option vest for every additional $2.50 in stock price above $10.00 per share for 20 consecutive trading days. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4)."}],"balance_after":1100000,"derivative":{"exercise_price":3.4,"expiration_date":"2027-10-09","underlying":"Common Stock","underlying_shares":1100000},"source":{"system":"sec-edgar","filing":"0000899243-17-029728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000089924317029728/doc4.xml","form_type":"4"}},{"id":4187871,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-11T22:13:03.000Z","date":"2017-10-09","kind":"grant","acquired":true,"shares":550000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option vests on October 9, 2018 and the remainder vests in equal monthly installments thereafter over a 3-year period. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4)."}],"balance_after":550000,"derivative":{"exercise_price":3.4,"expiration_date":"2027-10-09","underlying":"Common Stock","underlying_shares":550000},"source":{"system":"sec-edgar","filing":"0000899243-17-024054","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374690/000089924317024054/doc4.xml","form_type":"4"}},{"id":4324415,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-11T23:01:44.000Z","date":"2017-05-09","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable on the earlier of (i) May 09, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors."}],"balance_after":20000,"derivative":{"exercise_price":3.15,"expiration_date":"2027-05-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-17-031640","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339970/000120919117031640/doc4.xml","form_type":"4"}},{"id":4360147,"issuer":{"id":7233,"kind":"organization","name":"aTYR PHARMA INC"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-04-04T20:07:23.000Z","date":"2017-04-03","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning May 3, 2017, such that this option will be fully exercisable on April 3, 2020, subject to the recipient's continued service on the Issuer's Board of Directors."}],"balance_after":32000,"derivative":{"exercise_price":3.5,"expiration_date":"2027-04-03","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001209191-17-024676","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339970/000120919117024676/doc4.xml","form_type":"4"}},{"id":4567550,"issuer":{"id":94539,"kind":"organization","name":"INVIVO THERAPEUTICS HOLDINGS CORP.","symbol":"NVIV"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-11-03T19:13:52.000Z","date":"2016-11-01","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 24 equal installments on each monthly anniversary of the date of grant until fully vested on the 24-month anniversary of the date of grant."}],"balance_after":25000,"derivative":{"exercise_price":4.25,"expiration_date":"2026-11-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001179110-16-031183","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1292519/000117911016031183/edgar.xml","form_type":"4"}},{"id":4574971,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:33:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":60000,"price":12.22,"value":733200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 15, 2017 (the \"August 2017 Initial Vesting Date\") and 1/48th of the shares of stock which are subject to this option monthly following the August 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":8.78,"expiration_date":"2026-08-14","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-16-151945","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151945/a4.xml","form_type":"4"}},{"id":4574970,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:33:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":60000,"price":12.42,"value":745200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 15, 2017 (the \"February 2017 Initial Vesting Date\") and 1/48th of the shares of stock which are subject to this option monthly following the February 2017 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":8.58,"expiration_date":"2026-02-15","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-16-151945","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151945/a4.xml","form_type":"4"}},{"id":4574969,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:33:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":12.72,"value":636000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on August 14, 2016 (the \"August 2016 Initial Vesting Date\") and 1/48th of the shares of stock which are subject to this option monthly following the August 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":8.28,"expiration_date":"2025-08-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-16-151945","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151945/a4.xml","form_type":"4"}},{"id":4574968,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:33:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":6.6,"value":330000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option on February 13, 2016 (the \"February 2016 Initial Vesting Date\") and 1/48th of the shares of stock which are subject to this option monthly following the February 2016 Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":14.4,"expiration_date":"2025-02-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-16-151945","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151945/a4.xml","form_type":"4"}},{"id":4574967,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:33:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":134782,"price":13.87,"value":1869426.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option, which represented the unvested portion of a performance-based option granted on July 25, 2007, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":7.13,"expiration_date":"2021-03-22","underlying":"Common Stock","underlying_shares":134782},"source":{"system":"sec-edgar","filing":"0001104659-16-151945","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151945/a4.xml","form_type":"4"}},{"id":4574966,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:33:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":10320,"price":14.1,"value":145512.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":6.9,"expiration_date":"2020-03-23","underlying":"Common Stock","underlying_shares":10320},"source":{"system":"sec-edgar","filing":"0001104659-16-151945","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151945/a4.xml","form_type":"4"}},{"id":4574965,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:33:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":20869,"price":17.09,"value":356651.21,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":3.91,"expiration_date":"2019-01-20","underlying":"Common Stock","underlying_shares":20869},"source":{"system":"sec-edgar","filing":"0001104659-16-151945","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151945/a4.xml","form_type":"4"}},{"id":4574964,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:33:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":6245,"price":17.09,"value":106727.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":3.91,"expiration_date":"2018-01-29","underlying":"Common Stock","underlying_shares":6245},"source":{"system":"sec-edgar","filing":"0001104659-16-151945","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151945/a4.xml","form_type":"4"}},{"id":4574963,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:33:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":30434,"price":17.55,"value":534116.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested and was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":3.45,"expiration_date":"2017-09-25","underlying":"Common Stock","underlying_shares":30434},"source":{"system":"sec-edgar","filing":"0001104659-16-151945","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151945/a4.xml","form_type":"4"}},{"id":4574962,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-10-25T16:33:31.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":26086,"price":17.55,"value":457809.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option, which represented the vested portion of a performance-based option granted on July 25, 2007, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above."}],"balance_after":0,"derivative":{"exercise_price":3.45,"expiration_date":"2017-07-24","underlying":"Common Stock","underlying_shares":26086},"source":{"system":"sec-edgar","filing":"0001104659-16-151945","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151945/a4.xml","form_type":"4"}},{"id":4574961,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2016-10-25T16:33:31.000Z","date":"2016-10-24","kind":"other","acquired":false,"shares":244996,"price":21,"value":5144916.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc.  (\"Parent\") and Augusta Merger Sub, Inc. (\"Merger Sub\"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the \"Offer\") to purchase each outstanding share of the Company's Common Stock for $21.00 per share (the \"Offer Price\"), without any interest and subject to any tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at 12:00 midnight, New York City time, at the end of October 24, 2016, Merger Subsidiary accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share."}],"balance_after":244996,"source":{"system":"sec-edgar","filing":"0001104659-16-151945","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916151945/a4.xml","form_type":"4"}},{"id":4601651,"issuer":{"id":181526,"kind":"organization","name":"Vitae Pharmaceuticals, Inc","symbol":"VTAE"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2016-09-16T17:00:51.000Z","date":"2016-09-14","kind":"sale","acquired":false,"shares":50000,"price":20.81,"value":1040500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 25, 2015."}],"balance_after":244996,"source":{"system":"sec-edgar","filing":"0001104659-16-145191","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157602/000110465916145191/a4.xml","form_type":"4"}}]}